Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


AbbVie Hit Harder By EU Humira Biosimilars Than Projected

Executive Summary

The Q3 earnings call was the first time AbbVie management had to face the masses since the mid-October launch of adalimumab biosimilars across Europe. CEO Gonzalez predicted ex-US Humira revenue erosion of 26%-27% this year, higher than previous estimates.

You may also be interested in...

AbbVie Defends Humira With Aggressive Discount In First EU Tender

AbbVie has reportedly slashed the price of its TNF inhibitor Humira by 80% in the first European tender for biosimilar adalimumab, far beyond the 50% discount previously thought.

Sandoz And AbbVie Biosimilar Humira Settlement: What Does It Mean?

Sandoz has become the latest firm to sign a settlement agreement over biosimilar Humira with AbbVie, heralding imminent launch in Europe. In the US, it will hold off launching until September 2023.

Gilead’s HCV Authorized Generics Effort Will Draw Market Share From AbbVie

By marketing its own authorized generic versions of blockbuster HCV combos Epclusa and Harvoni, Gilead may eat into AbbVie’s large market share edge in US government-insured patients.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts